Clinical Trial: Effectiveness and Safety of a Novel Anal Insert Device for Treatment of Faecal Incontinence
Klinische Studie: Wirksamkeit und Sicherheit eines neuartigen Anal-Inserts zur Behandlung der Stuhlinkontinenz
Alimentary Pharmacology & Therapeutics · 2026-09 · 64 (5) · 603-614
DOI: 10.1111/apt.70831 ↗Auf einen Blick
Bei Patient:innen mit medikamentös bzw. konservativ refraktärer Stuhlinkontinenz war StaySure mit weniger Inkontinenzepisoden und besserer Lebensqualität verbunden. Schwere behandlungsbedingte Nebenwirkungen traten nicht auf.
Fragestellung
Wie wirksam und sicher ist das neue Anal-Insert StaySure bei Patient:innen mit Stuhlinkontinenz?
Methode
Patient:innen mit FI seit ≥ 6 Monaten und ≥ 4 moderaten oder großen Episoden in 4 Wochen; 2–4 Wochen Anpassungsphase und 4 Wochen Behandlung. Primärer Endpunkt: ≥ 50 % weniger FI-Häufigkeit.
Ergebnisse
Von 124 eingeschlossenen Patient:innen gingen 98, 71 und 61 durch Baseline-, Anpassungs- und Behandlungsphase. In der ITT-Kohorte von 59 sank die Zahl der Tage mit FI von 13,2 (7,0) auf 6,3 (6,9) und die Wochenepisoden von 5,4 (6,9) auf 2,1 (5,1) (69 %; p < 0,001).
Schlussfolgerung der Autor:innen
StaySure war sicher, gut verträglich und wirksam zur Reduktion von FI bei Patient:innen mit moderaten bis schweren Beschwerden trotz konservativer Therapien.
Kernaussagen
- Primärer Endpunkt bei 76,3 % erreicht
- FI-Wochenepisoden: 5,4 auf 2,1
- Keine behandlungsbedingten schweren unerwünschten Ereignisse
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
At a glance
Klinische Studie in Alimentary Pharmacology & Therapeutics, published online on 2026-07-21. Written by Adil E Bharucha and 6 co-authors. Institution: Division of Gastroenterology and Hepatology (Bharucha, Oblizajek, and Szarka), Department of Radiology (Fletcher), and Division of Clinical Trials an…. Major MEDLINE topics: Anal Canal, Fecal Incontinence. Cited 5 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: minnesota medical technologies.
Topics: Inkontinenz
Abstract (original language)
Background
Treatment options for medically‐refractory faecal incontinence ( FI )—including anorectal biofeedback, dextranomer injection, and sacral nerve stimulation—are limited and outcomes are often suboptimal. Anal or vaginal insert devices are infrequently used.
Aims
We evaluated the safety and effectiveness of a new anal insert device (StaySure) in patients with FI.
Methods
Patients with FI for ≥ 6 months and ≥ 4 moderate or large FI episodes during a 4‐week baseline entered a 2–4 week fitting/run‐in period to individualise device size (10 or 13 mm) followed by a 4‐week treatment period. Outcomes included effectiveness, safety, and quality of life (QoL). The primary outcome was the proportion achieving a ≥ 50% reduction in FI frequency.
Results
Of 124 enrolled patients, 98, 71, and 61 progressed through the baseline, fitting/run‐in, and treatment phases respectively, with few exclusions due to device intolerance. In the intent‐to‐treat cohort of 59 participants (93% women), mean ( SD ) number of days with FI declined from 13.2 (7.0) to 6.3 (6.9), and FI weekly episodes declined from 5.4 (6.9) to 2.1 (5.1) (69% reduction; p < 0.001) with similar results for both device sizes. The primary endpoint was achieved in 76.3% of participants; 54.2% achieved ≥ 75% reduction. The FIQoL overall score increased from a mean ( SD ) of 1.9 (0.6) to 2.3 (0.6) ( p < 0.001), indicating improved QoL . Improvements in FI frequency, FIQoL exceeded minimal clinically important difference thresholds, confirming clear clinical benefit. No treatment‐related serious adverse events were reported.
Conclusions
The StaySure anal insert device is safe, well tolerated, and effective in reducing FI in patients with moderate to severe symptoms refractory to conservative therapies. Trial Registration ClinicalTrials.gov identifier: NCT03898778
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Division of Gastroenterology and Hepatology (Bharucha, Oblizajek, and Szarka), Department of Radiology (Fletcher), and Division of Clinical Trials and Biostatistics (Bailey), Mayo Clinic, Mayo Clinic School of Graduate…
ORCID profiles: Nicholas R Oblizajek, Misha Gautam
Funding
- minnesota medical technologies
Cite
APA
Bharucha, A. E., Lamichhane, R., Fletcher, J. G., Oblizajek, N. R., Gautam, M., Bailey, K. R., & Szarka, L. A. (2026). Clinical Trial: Effectiveness and Safety of a Novel Anal Insert Device for Treatment of Faecal Incontinence. Alimentary Pharmacology & Therapeutics, 64(5), 603-614. https://doi.org/10.1111/apt.70831
Vancouver
Bharucha AE, Lamichhane R, Fletcher JG, Oblizajek NR, Gautam M, Bailey KR, et al. Clinical Trial: Effectiveness and Safety of a Novel Anal Insert Device for Treatment of Faecal Incontinence. Alimentary Pharmacology & Therapeutics. 2026;64(5):603-614. doi:10.1111/apt.70831
BibTeX
@article{Bharucha2026,
author = {Bharucha, Adil E and Lamichhane, Ramesh and Fletcher, Joel G and Oblizajek, Nicholas R and Gautam, Misha and Bailey, Kent R and Szarka, Lawrence A},
title = {Clinical Trial: Effectiveness and Safety of a Novel Anal Insert Device for Treatment of Faecal Incontinence},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
volume = {64},
number = {5},
pages = {603--614},
doi = {10.1111/apt.70831}
}
EUVIMED